| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Anatomy, Michigan State University, East Lansing, Michigan 48824 [C. W. W., C. K. B., M. G-S., J. C.] and IIT Research Institute, Chicago, Illinois 60616 [R. C. M.]
Two hundred forty Sprague-Dawley rats were treated i.v. with 2.5 or 1.25 mg of N-methyl-N-nitrosourea (MNU) per 100 g body weight at 50 and 57 days of age. At 60 days of age, rats given either dose were divided into 4 groups (30 rats/group) and treated as follows: Group 1, controls; Group 2, 0.4 mg 2-bromo-
-ergocryptine (CB-154) per 100 g body weight injected s.c. once daily; Group 3, retinyl acetate (328 mg/kg diet) fed daily; and Group 4, CB-154 and retinyl acetate treatments combined. Rats that received the 2.5-mg dose of MNU were treated for 129 days; those that received the 1.25-mg dose of MNU were treated for 175 days. The rats that were treated with the high dose of MNU were maintained without any treatment for an additional 13 weeks, after which they were sacrificed. The rats that were treated with the low dose of the carcinogen were sacrificed immediately after treatment. All rats were palpated once weekly for palpable mammary tumors. The number of rats with mammary tumors and the total number of mammary tumors at cessation of treatments were, respectively, as follows. MNU (2.5 mg); Group 1, 22 of 30 (73%), 82; Group 2, 11 of 30 (37%), 17; Group 3, 11 of 30 (37%), 19; Group 4, 2 of 30 (7%), 2. MNU (1.25 mg): Group 1, 8 of 30 (27%), 14; Group 2, 4 of 30 (13%), 5; Group 3, 3 of 30 (10%), 4; Group 4, 0 of 30, (0%), 0. Thus, chronic CB-154 treatment or retinyl acetate feeding markedly reduced the percentage of rats bearing mammary tumors and the total number of mammary tumors. The combined treatments were superior to either treatment alone, inasmuch as mammary tumorigenesis was nearly completely blocked in the rats of Group 4 that received the 2.5-mg dose of MNU and was totally blocked in the rats of Group 4 that received the 1.25-mg dose of MNU. Retinyl acetate feeding or CB-154-induced prolactin suppression appear to be equally effective treatments in the prophylaxis of MNU-induced mammary tumorigenesis in rats; the combined modality, however, appears to be far superior than either treatment alone.
1 Recipient of NIH Contract N01-CB-74090. To whom requests for reprints should be addressed.
2 Recipient of NIH Contract N01-CB-74207.
Received 1/28/80. Accepted 5/15/80.
This article has been cited by other articles:
|
|
 |
|
  S. M. McDaniel, C. O'Neill, R. P. Metz, E. Tarbutton, M. Stacewicz-Sapuntzakis, J. Heimendinger, P. Wolfe, H. Thompson, and P. Schedin Whole-Food Sources of Vitamin A More Effectively Inhibit Female Rat Sexual Maturation, Mammary Gland Development, and Mammary Carcinogenesis than Retinyl Palmitate J. Nutr., June 1, 2007; 137(6): 1415 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler The Role of Prolactin in Mammary Carcinoma Endocr. Rev., February 1, 2003; 24(1): 1 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rodriguez-Burford, R. A. Lubet, I. Eto, M. M. Juliana, G. J. Kelloff, C. J. Grubbs, and V. E. Steele Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model Carcinogenesis, January 1, 1999; 20(1): 71 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brinckerhoff, J. Coffey, and A. Sullivan Inflammation and collagenase production in rats with adjuvant arthritis reduced with 13-cis-retinoic acid Science, August 19, 1983; 221(4612): 756 - 758. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
